Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use

Eisai CEO Haruo Naito Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) is finally reaching the Japanese market later this month. CEO Haruo Naito on December 13 expressed his excitement about the launch, raising the development of a self-injectable subcutaneous form...read more